Dr. Hanna Tammam, a fellowship-trained hand, elbow, and shoulder surgeon in Lubbock, Texas, is the first U.S. physician to use TYBR Health’s B3 GEL System in a procedure, the company announced.

B3 GEL is a collagen-based tissue protector derived from extracellular matrix (ECM). Unlike physical barriers that can be difficult to place in tight anatomical spaces, the B3 GEL System is flowable and conforms to the tissue surface and maintains biomechanical separation during the critical healing window before being naturally resorbed. Recently published research on ECM-based hydrogels suggests these materials may interact with the early healing environment, creating conditions that allow the body’s native repair process to function properly. TYBR Health is continuing to evaluate the clinical performance of the B3 GEL System through post-market surveillance and real-world clinical use. 

“In a complex second-stage flexor tendon reconstruction—where balancing tissue protection with early rehabilitation is critical—I applied B3 GEL directly over the repair,” Dr. Tammam said. “The gel set within minutes, maintained excellent visualization, and allowed smooth tendon gliding without restricting motion. I subsequently used it in two additional flexor tendon repair cases, and across these early cases I observed consistently favorable early range of motion, minimal stiffness, and no complications—findings that are very encouraging in this patient population.”

TYBR Health will continue expanding the B3 GEL System’s clinical use while conducting post-market surveillance studies to gather real-world evidence on the product’s performance and patient outcomes across surgical settings.

“The first cases in the United States with the B3 GEL System represent a pivotal milestone for TYBR Health and for patients undergoing musculoskeletal surgeries”, TYBR Health Chief Commercial Officer Chris Wright stated. “These initial procedures mark the transition from regulatory clearance to real-world clinical application, allowing surgeons to directly address post-surgical tissue tethering—a complication that too often limits patient mobility and extends recovery times. By protecting healing tissues during the critical early phase, B3 GEL helps bridge the gap between surgical repair and functional success, enabling patients to regain movement faster and more completely. We’re excited to see these early outcomes that support our mission of improving quality of life for millions affected by tendon, ligament, and muscle procedures.”

TYBR Health develops solutions focused on protecting healing tissues after surgery, aiming to support functional restoration and improve the patient recovery experience. It’s lead product, the B3 GEL System, is cleared by the U.S. Food and Drug Administration to help protect soft tissues during post-surgical healing.